FDAIND申请CBL-514(一种新的减肥药物),使第二阶段的体重管理试验成为可能。 Caliway finishes FDA IND application for CBL-514, a new fat-reduction drug, enabling Phase 2 trials for weight management.

Caliway已完成了美国林业发展局调查新药物(IND)申请CBL-514(减肥药物候选者)的CBL-514(CBL-514),为以体重管理为重点的第二阶段临床试验铺平了道路。 Caliway has completed its U.S. FDA Investigational New Drug (IND) application for CBL-514, a fat reduction drug candidate, paving the way for a Phase 2 clinical trial focused on weight management. 该公司计划评估CBL-514,将其作为一种独立的治疗方法,并与GLP-1受体激动剂(GLP-1RA)疗法相结合,后者已经用于减肥。 The company plans to evaluate CBL-514 both as a standalone treatment and in combination with GLP-1 receptor agonist (GLP-1RA)-based therapies, which are already used for weight loss. 这一发展标志着在推动对肥胖症治疗采取潜在的新方法方面迈出的关键一步。 This development marks a key step in advancing a potential new approach to obesity treatment.